LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 34 of 497
Next
>>
>
826 to 850 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	R406	0.37	uM	LJP6	1	C16	72	hr	1657	5534	5505	1.0051	1.0074
BT-20	R406	0.37	uM	LJP6	2	C16	72	hr	1657	5535	5505	1.0053	1.0076
BT-20	R406	0.37	uM	LJP6	3	C16	72	hr	1657	5676	5505	1.0309	1.0443
BT-20	Pictilisib	0.37	uM	LJP6	1	D22	72	hr	1657	3272	5505	0.5943	0.4195
BT-20	Pictilisib	0.37	uM	LJP6	2	D22	72	hr	1657	3096	5505	0.5623	0.3738
BT-20	Pictilisib	0.37	uM	LJP6	3	D22	72	hr	1657	3241	5505	0.5887	0.4115
BT-20	Gefitinib	0.37	uM	LJP6	1	N10	72	hr	1657	5377	5505	0.9766	0.9666
BT-20	Gefitinib	0.37	uM	LJP6	2	N10	72	hr	1657	5378	5505	0.9768	0.9668
BT-20	Gefitinib	0.37	uM	LJP6	3	N10	72	hr	1657	4958	5505	0.9005	0.8577
BT-20	Geldanamycin	0.37	uM	LJP5	1	O04	72	hr	1657	1700	5505	0.3088	0.0110
BT-20	Geldanamycin	0.37	uM	LJP5	2	O04	72	hr	1657	1839	5505	0.3340	0.0471
BT-20	Geldanamycin	0.37	uM	LJP5	3	O04	72	hr	1657	1789	5505	0.3249	0.0341
BT-20	Geldanamycin	0.37	uM	LJP6	1	O04	72	hr	1657	1843	5505	0.3348	0.0481
BT-20	Geldanamycin	0.37	uM	LJP6	2	O04	72	hr	1657	1807	5505	0.3282	0.0388
BT-20	Geldanamycin	0.37	uM	LJP6	3	O04	72	hr	1657	1916	5505	0.3480	0.0671
BT-20	GSK1059615	0.37	uM	LJP5	1	E04	72	hr	1657	1756	5505	0.3189	0.0255
BT-20	GSK1059615	0.37	uM	LJP5	2	E04	72	hr	1657	2146	5505	0.3898	0.1269
BT-20	GSK1059615	0.37	uM	LJP5	3	E04	72	hr	1657	2082	5505	0.3782	0.1103
BT-20	GSK1059615	0.37	uM	LJP6	1	C04	72	hr	1657	1555	5505	0.2824	-0.0267
BT-20	GSK1059615	0.37	uM	LJP6	2	C04	72	hr	1657	1823	5505	0.3311	0.0429
BT-20	GSK1059615	0.37	uM	LJP6	3	C04	72	hr	1657	1808	5505	0.3284	0.0391
BT-20	GSK1904529A	0.37	uM	LJP6	1	H22	72	hr	1657	4934	5505	0.8962	0.8514
BT-20	GSK1904529A	0.37	uM	LJP6	2	H22	72	hr	1657	5329	5505	0.9679	0.9541
BT-20	GSK1904529A	0.37	uM	LJP6	3	H22	72	hr	1657	4939	5505	0.8971	0.8527
BT-20	Omipalisib	0.37	uM	LJP6	1	N04	72	hr	1657	1273	5505	0.2312	-0.1000

|<
<<
Previous
Page 34 of 497
Next
>>
>
826 to 850 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)